YAP1 and melanoma: Altogether, our data indicate that YAP1/TAZ induce the MAPKi-resistant MITFlow/AXLhigh phenotype in melanoma cells and likely contribute as upstream regulators to MAPKi resistance of BRAFV600E melanoma tumors in the clinic.